We are live on ! Find out more
ACHL

Achilles Therapeutics
ACHL

Delisted

ACHL was delisted on the 20th of March, 2025.

Back to rankings

18 hedge funds and large institutions have $19.4M invested in Achilles Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less capital invested

Capital invested by funds: $19.5M → $19.4M (-$123K)

22% less funds holding

Funds holding: 23 → 18 (-5)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
18
Holders Change
-5
Holders Change %
-21.74%
% of All Funds
0.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
5
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$307K
2
Millennium Management
Millennium Management
New York
+$49.3K
3
FA
Forefront Analytics
Pennsylvania
+$48.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$45.8K
5
UBS Group
UBS Group
Switzerland
+$13.4K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$1.45M
2
Renaissance Technologies
Renaissance Technologies
New York
-$113K
3
Jane Street
Jane Street
New York
-$40.8K
4
CF
Cantor Fitzgerald
New York
-$36K
5
VF
Virtu Financial
New York
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
SP
1
Syncona Portfolio
Guernsey
$10.6M – – –
BBA
2
Baker Bros. Advisors
New York
$2.48M – – –
AG
3
Artal Group
Luxembourg
$2.16M – – –
RG
4
Redmile Group
California
$1.54M – – –
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$1.35M – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$364K -$113K -104,500 -22%
Morgan Stanley
7
Morgan Stanley
New York
$272K +$307K +283,659 New
Axa
8
Axa
France
$270K -$2.61K -2,405 -0.8%
Millennium Management
9
Millennium Management
New York
$122K +$49.3K +45,494 +56%
FA
10
Forefront Analytics
Pennsylvania
$72.4K +$48.9K +45,100 +148%
Citadel Advisors
11
Citadel Advisors
Florida
$64.4K +$45.8K +42,252 +169%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$20.7K – – –
Bank of America
13
Bank of America
North Carolina
$14.6K +$5.01K +4,625 +43%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$13.3K – – –
UBS Group
15
UBS Group
Switzerland
$11.9K +$13.4K +12,379 New
JP Morgan Chase
16
JP Morgan Chase
New York
$1K – – –
RCM
17
RA Capital Management
Massachusetts
– -$1.45M -1,607,834 Closed
Jane Street
18
Jane Street
New York
– -$40.8K -45,332 Closed
CF
19
Cantor Fitzgerald
New York
– -$36K -40,000 Closed
VF
20
Virtu Financial
New York
– -$28K -31,003 Closed
E
21
Ergoteles
New York
– -$19.8K -22,004 Closed
TRCT
22
Tower Research Capital (TRC)
New York
– -$9K -9,772 Closed
Citigroup
23
Citigroup
New York
– -$599 -666 Closed
EWM
24
Endurance Wealth Management
Rhode Island
– +$2.17K +1,998 +99,900%

ACHL Hedge Fund Activity: Q1 2023 in Review

18 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2023, worth a combined $19.4M — down 0.63% from $19.5M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ACHL and 2 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 5 added.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $307K. The largest seller was RA Capital Management, exiting entirely with an estimated $1.45M sold.

  • 18 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2023, down from 23 in Q4 2022.
  • Funds reported $19.4M of Achilles Therapeutics stock for Q1 2023, down 0.63% quarter-over-quarter.
  • 2 funds opened new Achilles Therapeutics positions in Q1 2023 and 7 closed out, a net change of -5 holders.
  • The largest Achilles Therapeutics buyer in Q1 2023 was Morgan Stanley, an estimated $307K added.
  • The largest Achilles Therapeutics seller in Q1 2023 was RA Capital Management, an estimated $1.45M sold.

Based on aggregated 13F filings for Q1 2023.